If you have MDS, a type of blood cancer called myelodysplastic syndrome, you’re part of a rare group of people with the diagnosis. But research is ongoing. Many clinical trials are seeking new ...

This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors ...

Anthony Olson was told that he’d die without the treatment and to ignore a negative biopsy. He’s one of many patients who may ...

On the contrary, bone marrow examination continues to be a cornerstone in the diagnosis of MDS,” the authors wrote. “Given the complexity and subjectivity in the morphologic assessment of ...

"The message from this study should be to initiate tobacco cessation counseling in patients who carry a new diagnosis of MDS or its precursor conditions," said Venugoapal, who is the study's lead ...

Panelists discuss how mutational burden influences the duration of response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), as observed in the COMMANDS trial (Komrokji et al ...

Panelists discuss how mutational burden impacts the response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), highlighting its role in predicting treatment outcomes and the ...

myeloMATCH aims to expedite the development of tailored drug combination treatments for patients with newly diagnosed AML and MDS and to treat patients with these aggressive cancers of the blood ...

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations ; Trials to test tuspetinib in targeted dr ...

today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene ...